Education
About Us
Working with TipRanks
Follow Us
Relay Therapeutics (RLAY)
NASDAQ:RLAY
Total Valuation
Relay Therapeutics has a market cap or net worth of $605.20M. The enterprise value is -$219.81M.
Market Cap$605.20M
Enterprise Value-$219.81M
Share Statistics
Relay Therapeutics has 171,444,960 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding171,444,960
Owned by Insiders2.74%
Owned by Institutions0.14%
Financial Efficiency
Relay Therapeutics’s return on equity (ROE) is -0.43 and return on invested capital (ROIC) is -45.08%.
Return on Equity (ROE)-0.43
Return on Assets (ROA)-0.39
Return on Invested Capital (ROIC)-45.08%
Return on Capital Employed (ROCE)-0.45
Revenue Per Employee38.64K
Profits Per Employee-1.30M
Employee Count259
Asset Turnover0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Relay Therapeutics is ―. Relay Therapeutics’s PEG ratio is ―.
PE Ratio―
PS Ratio0.00
PB Ratio0.00
Price to Fair Value0.76
Price to FCF0.00
Price to Operating Cash Flow-2.18
PEG Ratio―
Income Statement
In the last 12 months, Relay Therapeutics had revenue of 10.01M and earned -337.71M in profits. Earnings per share was -2.36.
Revenue10.01M
Gross Profit4.54M
Operating Income-372.47M
Pretax Income-337.71M
Net Income-337.71M
EBITDA-372.47M
Earnings Per Share (EPS)-2.36
Cash Flow
In the last 12 months, operating cash flow was -271.99M and capital expenditures -622.00K, giving a free cash flow of -272.62M billion.
Operating Cash Flow-271.99M
Free Cash Flow-272.62M
Free Cash Flow per Share-1.59
Dividends & Yields
Relay Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.34
52-Week Price Change-48.68%
50-Day Moving Average3.45
200-Day Moving Average3.90
Relative Strength Index (RSI)47.84
Average Volume (3m)2.29M
Important Dates
Relay Therapeutics upcoming earnings date is Nov 5, 2025, Before Open (Confirmed).
Last Earnings DateAug 7, 2025
Next Earnings DateNov 5, 2025
Ex-Dividend Date―
Financial Position
Relay Therapeutics as a current ratio of 15.95, with Debt / Equity ratio of 6.54%
Current Ratio15.95
Quick Ratio15.95
Debt to Market Cap<0.01
Net Debt to EBITDA0.20
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Relay Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Relay Therapeutics EV to EBITDA ratio is -1.38, with an EV/FCF ratio of -2.04.
EV to Sales51.25
EV to EBITDA-1.38
EV to Free Cash Flow-2.04
EV to Operating Cash Flow-2.06
Balance Sheet
Relay Therapeutics has $93.54M in cash and marketable securities with $47.16M in debt, giving a net cash position of -$46.38M billion.
Cash & Marketable Securities$93.54M
Total Debt$47.16M
Net Cash-$46.38M
Net Cash Per Share-$0.27
Tangible Book Value Per Share$5.43
Margins
Gross margin is -12.15%, with operating margin of -3722.07%, and net profit margin of -3374.72%.
Gross Margin-12.15%
Operating Margin-3722.07%
Pretax Margin-3374.72%
Net Profit Margin-3374.72%
EBITDA Margin-3722.07%
EBIT Margin-3854.04%
Analyst Forecast
The average price target for Relay Therapeutics is $11.80, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$11.80
Price Target Upside238.11% Upside
Analyst ConsensusModerate Buy
Analyst Count6
Revenue Growth Forecast-78.26%
EPS Growth Forecast15.41%